Glucotrack Announced Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor
On May 13, 2025, Glucotrack, Inc., a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it received ethical approval from the St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) for its long-term clinical study of the Company’s continuous blood glucose monitor (“CBGM”) in participants with type 1 and type 2 diabetes.
The prospective, single-arm, multi-center study was set to enroll up to 30 participants with type 1 and type 2 diabetes mellitus ...